Successful treatment of primary plasma cell leukaemia by allogeneic stem cell transplantation from haploidentical sibling

Atsushi Nonami, Toshihiro Miyamoto, Mika Kuroiwa, Yuya Kunisaki, Kenjiro Kamezaki, Katsuto Takenaka, Naoki Harada, Takanori Teshima, Mine Harada, Koji Nagafuji

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

Primary plasma cell leukaemia (PCL) is a rare, aggressive neoplasm of plasma cell dyscrasia. Conventional chemotherapy is usually ineffective, with an overall survival of only 8 months. Here, we describe a 42-year-old man with primary PCL, who was successfully treated with haploidentical (2-HLA loci mismatched) haematopoietic stem-cell transplantation (HSCT). To overcome the human leukocyte antigen (HLA) disparity, in vivo T-cell purging by the pre-transplant administration of antithymocyte globulin followed by a conventional prophylactic treatment against graft-versus-host disease (GVHD) resulted in an avoidance of severe GVHD as well as infectious complications. The patient has maintained complete remission for 13 months after haploidentical HSCT, indicating that a graft-versus-PCL effect might be preserved. Haploidentical HSCT can be a potentially curative treatment for patients with primary PCL who do not have an HLA-identical donor.

Original languageEnglish
Pages (from-to)969-972
Number of pages4
JournalJapanese journal of clinical oncology
Volume37
Issue number12
DOIs
Publication statusPublished - Dec 1 2007

    Fingerprint

All Science Journal Classification (ASJC) codes

  • Oncology
  • Radiology Nuclear Medicine and imaging
  • Cancer Research

Cite this